Background: Salvage high-intensity focused ultrasound (HIFU) and cryotherapy (CRYO) have emerged as interesting alternatives in the treatment of local radio-recurrent prostate cancer. Currently, recommendations concerning the use of CRYO and HIFU in the salvage setting are still evolving. Aim: The objective of this review was to analyze the results from studies on CRYO and HIFU as salvage treatment in local radio-recurrent prostate cancer. Materials and Methods: A National Center for Biotechnology Information PubMed search (www.pubmed.gov) was conducted from 1993 to 2011 using medical subject headings ‘High-Intensity Focused Ultrasound’, ‘Cryotherapy’, ‘Local Radio-Recurrent’ and ‘Prostate Cancer’. Results: In the past years, there have been several published series demonstrating promising acceptable morbidity and oncological outcomes in the short term for HIFU and in the intermediate term for CRYO. The introduction of newer-generation devices and technical modifications has facilitated reduction of complications associated with the procedures. As with any salvage treatment, careful patient selection and subsequent follow-up are principal points. Conclusions: HIFU and CRYO are promising salvage treatments in patients with local radio-recurrent prostate cancer. The risk of significant complications in the salvage setting is higher compared with primary therapy; therefore, the patients must be informed about the risk of complications and the modality of treatment. However, only further evaluation in formal prospective clinical trials will hopefully confirm their role in clinical practice.

External beam radiotherapy (EBRT) and interstitial brachytherapy are used commonly in the treatment of localized prostate cancer. However, an estimated 20–30% of patients present fail after radiotherapy (RT) treatment. Patients with isolated local recurrence and life expectancy over 5 years may benefit from and be offered some form of local salvage therapy, with curative intent [1]. The management of local radio-recurrent prostate cancer is controversial and there is no consensus regarding the optimal strategy. The decision is often based on biological tumor features, patient age and comorbidities, as well as patient and physician preferences and physician expertise. The vast majority of these patients currently receive androgen-deprivation therapy (ADT), which is non-curative, although it would be appropriate for patients with a short life expectancy or metastatic disease [2]. Salvage radical prostatectomy (RP) is an established treatment option, which offers the greatest likelihood of secondary control, although it is generally associated with a higher morbidity rate [3]. Minimally invasive therapies such as high-intensity focused ultrasound (HIFU) and cryotherapy (CRYO) have emerged as alternatives showing encouraging results in terms of morbidity rates and cancer control [4]. Currently, HIFU is undergoing FDA trials in the USA and Canada, although it has been approved as a therapeutic option in many European countries. However, the global experience of HIFU as salvage therapy is still limited. Experience with salvage CRYO has been accumulating over the past decade, having benefited from some technological advances. This article reviews the current literature on HIFU and CRYO as whole-gland ablative salvage therapy and evidence for their efficacy and morbidity in localized radio-recurrent prostate cancer.

There is no consensus on the definition for biochemical failure after RT. As CRYO and HIFU are both ablative rather than excisional procedures such as RP, comparison of biochemical-free survival rates of the various modalities without taking into account the presence of residual benign prostate-specific antigen (PSA) secreting tissue is not ideal [5]. It is also perhaps unreasonable to compare the definition of PSA failure with that of EBRT which is not a true ablative procedure. Thus there has been a significant variation in the reporting of disease-free survival (DFS) rates with investigators using either the American Society for Therapeutic Radiology and Oncology (ASTRO) definition [6] of three consecutive PSA rises after nadir or the Phoenix definition of nadir + 2 ng/ml [7,8]. Blana et al. [9], in a recent study with salvage HIFU patients using the Ablatherm system, highlighted the high sensitivity and low specificity of the ASTRO definition versus the low sensitivity and high specificity of the Phoenix criteria. The group proposed the ‘Stuttgart’ definition of PSA nadir + 1.2 ng/ml, although since a significant proportion of their patients had undergone prior transurethral resection of the prostate. Thus this definition may not be widely applicable to all salvage HIFU patients. Many studies on short-term outcomes following CRYO have high and perhaps misleading DFS. For this reason, many authors use prostate biopsy at 6–12 months following salvage treatment as an indicator for recurrence. However, Shinohara et al. [10] have shown that biopsy failure could be strongly predicted by a PSA nadir >0.5 ng/ml (55%) as compared to PSA nadir <0.4 and <0.1 ng/ml at 10 and 1.5% respectively.

The choice of an adequate salvage therapy is dependent on appropriate patient’s evaluation. As with any salvage treatment, it is mandatory to attain histological confirmation of tumor recurrence and exclude metastatic disease with abdominal and pelvic magnetic resonance imaging (MRI) or computerized tomography and 99Tc bone scan. In addition, the candidates must also have a sufficiently long life expectancy to justify the use of a potentially morbid treatment rather than a non-curative option such as ADT. A histologic Gleason score <8 as well as PSA <4.0 ng/ml prior to salvage treatment have been shown to be good predictors of 5-year DFS [11].

Positive prostate biopsies are currently the only way to confirm local recurrence but there is significant controversy regarding the role and reliability of biopsy following RT. Histologic analysis is complicated by radiation changes, which may mimic high-grade disease, thereby conceivably leading to an inaccurate Gleason score of false positive results [12]. Within the first 12–24 months following RT, prostate biopsy should be interpreted with caution due to delayed apoptotic cell death [13]. Crook et al. [14] reported that about 30% of positive biopsies obtained at 12 months covert to a negative status by 24–30 months, while about 20% of patients who have a negative posttreatment biopsy will later have a positive repeat biopsy.

Detection of occult local recurrence and distant metastasis in radio-recurrent prostate cancer may be possible with 11C or 18-fluorocholine PET scans [15]. Rinnab et al. [16] reported a sensitivity of 89% with a positive predictive value of 72% for recurrence detection at PSA <2.5 ng/ml.

HIFU was introduced as a treatment option for prostate cancer in the 1990s. HIFU works by focusing ultrasound waves on a specific target of prostate tissue using a transrectal ultrasound probe, producing thermal and mechanical effects in the prostatic tissue with subsequent coagulative necrosis, generating lesions through a direct dose-related effect.

Technology

There are currently two commercially available HIFU units in clinical use. The AblathermTM device (EDAP-TMS SA, Vaulx-en-Velin, France) is the device more commonly used in Europe and Asia. The Sonoblate 500 (Focus Surgery Inc., Indianapolis, Ind., USA) is in use in Central and South America and is currently undergoing trials in Canada and the USA. It is important to realize that these two devices have specific differences with regard to limitations on patient selection as well as technical differences in intraoperative monitoring. Table 1 shows a comparison of the two available high-intensity focusing ultrasound devices.

Table 1

Characteristics of HIFU devices

Characteristics of HIFU devices
Characteristics of HIFU devices

Oncological Outcomes

HIFU shows promise as a salvage treatment. Currently there is only limited published literature with respect to the follow-up duration, as would be expected with a new treatment modality. Studies have mean follow-up between 3 and 39 months and DFS rates of between 25 and 54% [17,18,19] (table 2).

Table 2

Salvage HIFU in local radio-recurrent prostate cancer

Salvage HIFU in local radio-recurrent prostate cancer
Salvage HIFU in local radio-recurrent prostate cancer

Murat et al. [19] reported 73% DFS at 18.1 months. Similarly, Colombel et al. [20] reported, in control biopsies after salvage HIFU using the AblathermTM system, a negative biopsy rate of 80% at 15 months. Published data for CRYO and brachytherapy have reported negative biopsy rates between 77 and 86% respectively [21].

Independent predictors for risk of disease progression have been analyzed in different series. Patients who had received hormonal therapy prior to salvage HIFU were 2.8 times more at risk of disease progression compared to patients who did not. The presalvage PSA level is most important and has been identified as an independent predictive factor for progression. In contrast, the presalvage Gleason score and percentage of positive biopsies are not significantly linked to treatment failure and disease progression [22].

Morbidity

As expected, morbidity rates of salvage HIFU are higher compared to primary HIFU treatment. However, they compare favorably to salvage RP in terms of urinary incontinence rates [17,18,19]. Since the risk of rectourethral fistula following RT increases due to poor tissue viability and poor periprostatic blood supply precluding effective tissue repair, this complication has been reported to be from 3 to 12.5% of patients [19]. Evidence related to other patient-relevant outcomes is limited to adverse events of the urinary tract such as bladder neck contracture or urethral stricture at 10–20%, urinary tract infection from 1 to 6%, and prolonged urinary retention at 6% [17,18,19].

Failure following Salvage HIFU

Postprocedural prostate biopsy is performed routinely by some surgeons and only if clinically indicated by others. PSA nadir is generally reached between 6 and 12 months, and is generally regarded as the ideal time for biopsy [22]. Uchida et al. [23] showed that patients with a PSA nadir <0.2 ng/ml had a low rate of cancer detection on post-HIFU biopsy of only 11%, as compared to 54 and 52% if the PSA nadir was 0.21–1.00 or >1 ng/ml respectively. This has led to some investigators suggesting that routine biopsy may not be required in patients with a PSA nadir <0.2 ng/ml. However, further studies are required to validate this assertion, especially given the relatively low morbidity of repeat HIFU treatment in these patients. Preliminary results suggest that dynamic contrast-enhanced MRI may provide accurate detection of local recurrence following HIFU, with a sensitivity and specificity of 0.98 and 0.81 respectively [24]. This may be promising as a postoperative monitoring modality.

HIFU is a procedure that is theoretically repeatable and reproducible despite previous HIFU treatment [25]. Clinical experience with repeat HIFU, however, has been limited, with a small percentage of cases from several reported HIFU series. One needs to be cautioned about incremental risks of complications such as fistula formation and incontinence if repeat HIFU is contemplated.

CRYO now is a well-established treatment option in the salvage setting with approval by the FDA attained as early as 1999 for primary therapy. Contemporary CRYO is performed transperineally with transurethral ultrasound guidance of probes and real-time monitoring of the procedure. Recent advances in third-generation technology have resulted in less morbidity whilst maintaining efficacy.

Different mechanisms of cell death have been implicated in the efficacy of CRYO [26]. A key mechanism is the induction of ice crystals within the prostate cancer cells which results in physical disruption of the cells. Crystallization and cellular death begin when the temperature falls below 0°C within the prostate cells. However, adequate tissue destruction and resultant coagulative necrosis requires significantly lower temperatures of at least –40°C. Ideally, once temperatures reach –40°C, the cells would break down to allow maximal destruction of the cellular matrix, resulting in cellular death. Intracellular changes such as protein denaturation damages and electrolyte and osmotic changes are also part of the cytocidal process. At the extracellular level, thromboses of the microvasculature and tissue matrix destruction also contribute to destruction of the prostate gland.

Technology

Whilst first-generation CRYO had little in the way of safeguards against collateral damage other than the vigilance of the operating surgeon, modern CRYO units have numerous safety features to reduce the complications associated with the procedure. Ice-ball formation is monitored real-time with transurethral ultrasound including three-dimensional views employed at some centers [27]. The use of thermocouplers in areas of interest allows us to protect areas such as the external urinary sphincter and rectal wall to reduce the risk of incontinence and fistula formation respectively by careful monitoring against excessive freezing. Active warming is now performed on the urethra via closed systems that irrigate warm fluid allowing the mucosa to stay warm throughout the procedure, thus reducing the risk of urethral sloughing. Various maneuvers, including prerectal placement of protective balloons and injection of special fluids into the perineum, have been used to protect the rectum. Improved computerized systems allow more reliable treatment planning, more predictable treatment patterns, improved visual monitoring [27,28,29] and, at least in theory, a lower risk of cryo-damage to important structures whilst ensuring adequate freezing of malignant tissue.

Oncological Outcomes

As mentioned previously, there is no standardized definition of failure following salvage CRYO. Most physicians recommend repeat prostate biopsy at 6 months to check for viable tumor tissue. Salvage CRYO can be repeated if viable prostate cancer tissue is found. However, as with repeat salvage HIFU, there is always concern of increased risk of fistula formation and incontinence. Published data in terms of DFS have achieved ranges from 11 to 73% at 5 years [30,31]. Data from our institution have shown a DFS rate at 10 years of between 39 and 64% with presalvage PSA <5 ng/ml and presalvage Gleason score ≤7 being the best predictor of disease-free recurrence at 10 years [32]. Recently, Philippou et al. [33] have reported a DFS rate at 2 years of 58% with a median PSA nadir of 0.20 ng/ml. A summary of available studies is included in table 3.

Table 3

Salvage CRYO series in local radio-recurrent prostate cancer

Salvage CRYO series in local radio-recurrent prostate cancer
Salvage CRYO series in local radio-recurrent prostate cancer

The PSA level at the time of salvage CRYO has been reported to be an important prediction factor for disease progression [32]. In a post-RT setting, Ng et al. [11] from our center reported a 5-year biochemical recurrence-free survival of 56 versus 1% for presalvage CRYO PSA <4 and >10 ng/ml respectively. Similarly, Izawa et al. [34] reported than patients with PSA <10 ng/ml presented DFS 57 versus 23% for PSA >10 ng/ml at 5 years respectively.

Pisters et al. [35] reported on a case-control comparative study comparing salvage CRYO with salvage RP, performed at separate institutions respectively. Unfortunately as with all case-control comparisons there was a degree of bias in the selection of patients. However, Pisters et al. showed that salvage RP was associated with an increased DFS rate using definitions of failure of PSA nadir <0.4 ng/ml and two rises above PSA nadir. This underscores that the gold standard remains complete surgical removal of recurrent prostate cancer for patients capable of undergoing a more invasive surgical procedure. However, CRYO still maintains a strong fallback option for patients with relative contraindications to salvage RP or preference for a minimally invasive approach.

Morbidity

Side effects of salvage CRYO are more prevalent and serious compared with those reported in the primary setting. With improvements in CRYO devices and techniques, the incidence of complications has decreased with time. Urinary incontinence rates ranging from 10.5 to 36% [21,33] in comparison to incontinence rates of 41% reported in salvage RP, whilst the fistula rates were from 2.6 to 5.3% [22,33], have been reported with CRYO in comparison with rectal injury rates from 2 to 15% with salvage RP. The risk of complications seems to be higher in the presence of prior transurethral surgery. Prior transurethral resection of the prostate increases the risk of incontinence with salvage CRYO, reported in 6.7% [36]. Langenhuijsen et al. [37] have reported urethral stricture ranges from 0 to 5% and sexual function recovery in only 14% of patients submitted to salvage CRYO with a modified technique. One of the more common and problematic complications of CRYO is perineal pain. This has been reported to occur in up to 8% in patients series [37].

Failure following Salvage Cryotherapy

A PSA nadir of >1 ng/ml post-CRYO usually portends inevitable disease-free recurrence as does a presalvage PSA >10 ng/ml [32]. Thus patients with a PSA >10 ng/ml are poor candidates for salvage and any patient who does not attain a nadir <1 ng/ml, regardless of presalvage PSA, should be considered for early alternative therapy such as androgen deprivation. Although CRYO can be repeated for biopsy-proven local recurrence of prostate cancer following salvage CRYO, biochemical recurrence without biopsy-proven recurrence strongly suggests metastatic recurrence and thus repeat CRYO is not appropriate without (a) repeat histological confirmation of local disease persistence and (b) repeat metastatic work-up. As with repeat salvage HIFU, one can anticipate with repeat salvage CRYO a higher risk of fistula formation and urinary incontinence [11].

The available published literature is variable regarding a standardized follow-up protocol and the use of definitions following salvage therapy. The principal key of follow-up in radio-recurrent prostate cancer is based on periodic serum PSA measurements and surveillance for possible local or distant recurrence. Policies on posttreatment prostatic biopsy have been variable, with some authors adhering to strict biopsy routines and others using a more ad-hoc approach. Current evidence supports the practice of routine PSA levels in addition to a posttreatment biopsy performed 6–12 months postoperatively [38].

This review has dealt only with whole-gland salvage HIFU and CRYO ablation.Recent reports have highlighted that although prostate cancer is a multifocal disease, frequently an ‘index lesion’ is the only significant cancer lesion [39,40]. Although current experience has been mainly limited to whole-gland ablation, focal salvage therapy is now conducted at some centers. Proper patient selection remains a challenge. Ongoing advances in prostate functional imaging modalities as well as molecular oncology should improve accurate cancer localization as well as tumor grading and risk stratification. Focal salvage therapy with selective lesion-directed ablation instead of whole-gland ablation would merit clinical trials.

Whole-gland CRYO and HIFU have emerged as alternatives for the treatment of local radio-recurrent prostate cancer in patients with relative contraindications to salvage RP. Currently, there is no consensus on the use of these modalities in the salvage setting, as there is a lack of long-term follow-up and a paucity of evidence concerning improved quality of life and improved cancer-specific survival.

In fact, the current evaluation of oncological outcomes following salvage HIFU or CRYO remains a challenge for the urologist. A variety of definitions of PSA relapse in a heterogeneous population have been used. As yet, none of these definitions have been validated against clinical progression or survival and therefore, it is not possible to give firm recommendation on the definition of failure. In this context, an acceptable definition of disease control is required. We believe that one definition based on a predictive model can be a potential solution in clinical practice. Firstly, one needs to create a model that includes biological and histopathological variables according to the patient’s risk stratification and the use of ADT and/or RT in order to estimate the risk of treatment failure. Secondly, new imaging modalities such as multiparametric MRI with image-guided biopsies performed systematically during follow-up to discriminate between local and systemic failure, reducing the significance of false negative results, will be relevant. Thirdly, an accurate interpretation of prostatic biopsies by an expert uropathologist is required due to difficulties in the identification of residual malignant tissue and the differentiation of histologic effects produced by ADT, EBRT, CRYO or HIFU.

In terms of morbidity, HIFU and CRYO have been considered as alternative options in the salvage setting to patients with comorbidities rendering them suboptimal for surgery. Although both are considered minimally invasive modalities, the risk of significant complications in the salvage setting is higher compared with primary therapy and the nature of the complications is inherent to the procedure. Thus, the patients must be informed about the risk of complications and modality of treatment. Ongoing technologic advancement and technical improvements will further reduce procedure-related complications and increase clinical applicability and patient acceptance.

HIFU and CRYO are promising salvage treatment alternatives in patients who have localized failure after RT. A careful selection of patients for mini-invasive treatment is mandatory due the risk of significant complications inherent to salvage treatment. The patients must therefore be informed about the risk of complications and the modality of treatment. However, only further evaluation in formal prospective clinical trials will hopefully confirm their role in clinical practice.

1.
Zietman AL, Bae K, Slater JD: Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology. J Clin Oncol 2010;28:1106–1111.
2.
Agarwal PK, Sadetsky N, Konety BR, Resenick MI, Carroll PR: Cancer of the prostate Strategic Urological Research Endeavor (CAPSURE). Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care and outcomes. Cancer 2008;112:307–314.
3.
D’Amico A, Altschuler M, Whittington R, Kao G, Malkowicz SB, Wein A: The use of clinical parameters in an interactive statistical package to predict pathological features associated with local failure after radical prostatectomy for prostate cancer. Clin Perform Qual Health Care 1993;1:219–222.
4.
Prepelica KL, Okeke Z, Murphy A, Katz AE: Cryosurgical ablation of the prostate: high-risk patient outcomes. Cancer 2005;103:1625–1630.
5.
Chin JL, Touma N, Pautler SE, Guram KS, Bella AJ, Downey DB, et al: Serial histopathology results of salvage cryoablation for prostate cancer after radiation failure. J Urol 2003;170:1199–1202.
6.
American Society for Therapeutic Radiology and Oncology Consensus Panel: Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035–1041.
7.
Pickles T, Kim-Sing C, Morris WJ, Tyldesley S, Paltiel C: Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys 2003;57:11–18.
8.
Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965–974.
9.
Blana A, Murat FJ, Walter B, Thuroff S, Wieland WF, Chaussy C, et al: First analysis of the long-term results with transrectal HIFU in patients with localized prostate cancer. Eur Urol 2008;53:1194–1201.
10.
Shinohara K, Rhee B, Presti JC Jr, Carroll PR: Cryosurgical ablation of prostate cancer: patterns of cancer recurrence. J Urol 1997;158:2206–2210.
11.
Ng CK, Moussa M, Downey DB, Chin JL: Salvage cryoablation of the prostate: follow-up and analysis of predictive factors for outcome. J Urol 2007;178:1253–1257.
12.
Bostwick DG, Egbert BM, Fajardo LF: Radiation injury of the normal and neoplastic prostate. Am J Surg Pathol 1982;6:541–551.
13.
Molinié V, Mahjoub WK, Balaton A: Histological modifications observed in prostate after preserving treatments for prostate cancer and their impact on Gleason score interpretation. Ann Pathol 2008;28:363–373.
14.
Crook J, Malone S, Perry G, et al: Post-radiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 2000;48:355–367.
15.
Pucar D, Sella T, Schoder H: The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. Curr Opin Urol 2008;18:87–97.
16.
Rinnab L, Simon J, Hautmann RE, et al: Choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J Urol 2009;27:619–625.
17.
Mallick S, Dufour A, Fouques Y, Bensadoun H: Salvage therapy using high-intensity focused ultrasound for local recurrence of prostate cancer after radiation therapy (abstract). Eur Urol Suppl 2006;5:132.
18.
Gelet A, Chapelon J, Poissonnier L, Bouvier R, Colombel M, Curiel L, et al: Local recurrence of prostate cancer after external beam radiation: early experience of salvage therapy using high-intensity focused ultrasound (abstract. Eur Urol Suppl 2006;5:133.
19.
Murat FJ, Poissonnier L, Rabilloud M, Belot A, Bouvier R, Rouviere O, et al: Mid-term results demonstrate salvage high-intensity focused ultrasound as an effective and acceptably morbid salvage treatment option for locally radio-recurrent prostate cancer. Eur Urol 2009;55:640–647.
20.
Colombel M, Poissonier L, Martin X, Gelet A: Clinical results of the prostate HIFU project. Eur Urol Suppl 2006;5:491–494.
21.
Nguyen P, D’Amico AV, Lee AK, Su WW: Patient selection, cancer control and complications after salvage local therapy for post- radiation prostate-specific antigen failure. Cancer 2007;110:1417–1428.
22.
Poissonnier L, Chapelon JY, Rouviere O, Curiel L, Bouvier R, Martin X, et al: Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007;51:381–387.
23.
Uchida T, Illing RO, Cathcart PJ, Emberton M: To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int 2006;98:537–539.
24.
Ben Cheikh A, Girouin N, Ryon-Tapponier P, et al: MR detection of local prostate cancer recurrence after transrectal high-intensity focused ultrasound treatment: preliminary results. J Radiol 2008;89:571–577.
25.
Blana A, Rogenhofer S, Ganzer R, Wild PJ, Wieland WF, Walter B: Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer. World J Urol 2006;24:585–590.
26.
Cooper IS, Hirose T: Application of cryogenic surgery to resection of parenchymal organs. N Engl J Med 1966;274:15–18.
27.
Chalasani V, Gardi L, Martinez CH, Downey DB, Fenster A, Chin JL: Contemporary technique of intraoperative three-dimensional ultrasonography-guided transperineal prostate cryotherapy. Can Urol Assoc J 2009;3:136–141.
28.
Chin JL, McLoughlin RF, Downey DB: Three-dimensional ultrasound and magnetic resonance imaging of pelvic anatomy: potential for complications from minimally invasive procedures. J Endourol 1999;13:451–459.
29.
Chin JL, Downey DB, Onik G, Fenster A: Three-dimensional prostate ultrasound and its application to cryosurgery. Tech Urol 1996;2:187–193.
30.
Ghafar MA, Johnson CW, De La Taille A, et al: Salvage cryotherapy using argon-based system for locally recurrent prostate cancer after radiation therapy: the Columbian Experience. J Urol 2001;166:1333–1337.
31.
Ismail M, Ahmed S, Kastner C, Davies J: Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int 2007;100:760–764.
32.
Williams AK, Martinez CH, Lu C, Ng CK, Pautler SE, Chin JL: Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer. Eur Urol 2011;60:405–410.
33.
Philippou P, Yap T, Chinegwundoh F: Third-generation salvage cryotherapy for radio-recurrent prostate cancer: a centre’s experience. Urol Int 2012;88:137–144.
34.
Izawa JI, Madsen LT, Scott SM, et al: Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol 2002;20:2664–2671.
35.
Pisters LL, Leibovici D, Blute M, Zincke H, Sebo TJ, Slezak JM, et al: Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol 2009;182:517–527.
36.
Chin JL, Pautler SE, Mouraviev V, et al: Results of salvage cryoablation for prostate cancer after radiation: identifying predictors of treatment failure and complications. J Urol 2001;165:1937–1941.
37.
Langenhuijsen JF, Broers ESP, Vergunst H: Cryosurgery for prostate cancer: an update on clinical results of modern cryotechnology. Eur Urol 2009;55:76–86.
38.
Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J: Male lumpectomy focal therapy for prostate cancer using cryoablation. Urology 2007;70:16–21.
39.
Karavitakis M, Winkler M, Abel P, Livni N, Beckley I, Ahmed HU: Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis 2011;14:46–52.
40.
Bott SR, Ahmed HU, Hindley RG, Abdul-Rahman A, Freeman A, Emberton M: The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. BJU Int 2010;106:1607–1611.
41.
Benoit RM, Cohen JK, Miller RJ: Cryosurgery for prostate cancer: new technology and indications. Curr Urol Rep 2000;1:41–47.
42.
Bahn DK, Lee F, Silverman P, et al: Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-year follow-up. Clin Prostate Cancer 2003;2:111–114.
43.
Donnelly BJ, Saliken JC, Ernst DS, et al: Role of transrectal ultrasound-guided salvage cryosurgery for recurrent prostate carcinoma after radiation therapy. Prostate Cancer Prostatic Dis 2005;8:235–242.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.